Brands
Pfizer India posts Rs 722 crore profit despite softer Q4 show
Revenue rises to Rs 2,519 crore in FY26 as margins stay resilient
MUMBAI: Pfizer may sell medicines, but this quarter the company also prescribed a familiar corporate remedy, steady margins, sharp cost control and a healthy cash pile to soothe a softer earnings patch. Pfizer India reported a net profit of Rs 722.43 crore for the financial year ended March 31, 2026, even as the pharmaceutical major closed the final quarter on a more measured note after a high base in the previous year.
Revenue from operations for FY26 rose to Rs 2,519.65 crore from Rs 2,281.35 crore a year earlier, while total income climbed to Rs 2,707.60 crore compared with Rs 2,453.60 crore in FY25.
Annual profit before tax stood at Rs 975.67 crore. However, unlike the previous year, the numbers did not receive a boost from one-off exceptional gains. In FY25, Pfizer had booked an exceptional gain of Rs 172.81 crore linked to the assignment of land and building assets. In FY26, exceptional items swung negative at Rs 49.16 crore.
Strip away those exceptional swings, though, and the company’s core business still showed resilience. Profit after tax for FY26 came in at Rs 722.43 crore against Rs 767.60 crore in the previous year, while earnings per share stood at Rs 157.92 compared with Rs 167.79 in FY25.
The March quarter itself reflected a mixed prescription. Revenue from operations rose to Rs 629.23 crore from Rs 591.91 crore in the corresponding quarter last year. Profit before tax for the quarter came in at Rs 268.82 crore, sharply lower than Rs 425.80 crore a year earlier, largely due to the absence of last year’s exceptional gain and higher operating pressures.
Quarterly net profit stood at Rs 199.82 crore, compared with Rs 330.94 crore in the year-ago period.
Despite the softer quarter, Pfizer continued to flex its financial muscle through a strong balance sheet and hefty cash reserves. Cash and bank balances, including deposits, stood at more than Rs 3,110 crore at the end of FY26, underlining the company’s liquidity strength.
The company also generated robust operating cash flow of Rs 967.57 crore during the year, although financing activities reflected a large dividend payout of Rs 751.64 crore.
Operationally, employee benefit expenses for FY26 remained largely stable at Rs 367.97 crore, while material and stock-related costs rose alongside business growth. Total annual expenses increased to Rs 1,682.77 crore from Rs 1,610.32 crore.
The results arrive at a time when India’s pharmaceutical sector continues to navigate pricing pressures, regulatory scrutiny and shifting global supply-chain dynamics, even as domestic demand for chronic therapies and speciality medicines remains strong.
Pfizer’s numbers suggest the company is still comfortably in the pink of health, even if this quarter lacked the blockbuster boost of last year’s exceptional gains.
